Pharmaceuticals: Survival of the 'Fittest': AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline and Wyeth: Can competitive advantage be sustained without M&A in the wake of Pfizer/Pharmacia?
Datamonitor January 7, 2003 37 Pages - Pub ID: DFMN855793
Enter a term to search inside this document.
Learn more.
Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).
Please note that your term must be at least 4 characters long and numbers will be blocked by the # sign.
(0 items)
